NASDAQ:FOLD - Nasdaq - US03152W1099 - Common Stock - Currency: USD
We recently published a list of 10 Best Low Priced Biotech Stocks to Buy Now. In this article, we are going to take a look at where Amicus Therapeutics, Inc. (NASDAQ:FOLD) stands against other best low priced biotech stocks to buy now. Is Now the Time to Buy Biotech Stocks? On May 8, Michael Yee, […]
BHCs first-quarter 2025 adjusted earnings and revenues miss estimates. Salix performs lower than expected. Stock declines.
AFRM, TKOMY, FOLD, MASS and VFC have been added to the Zacks Rank #1 (Strong Buy) List on April 1, 2025.
1Q 2025 Total Revenue of $125.2M, a 15% Increase Year-over-Year at CER Expanding Portfolio through In-Licensing of DMX-200 Phase 3 Program for Rare Kidney...
Amicus licenses exclusive U.S. rights to commercialize DMX-200 for the treatmentof Focal Segmental Glomerulosclerosis (FSGS) DMX-200 is in a pivotal Phase...
YmAbs Therapeutics (YMAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mentions: YMAB
Amicus Therapeutics (FOLD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
We recently published a list of 11 Best Guru Stocks to Buy According to Wall Street Analysts. In this article, we are going to take a look at where Amicus Therapeutics, Inc. (NASDAQ:FOLD) stands against other Guru stocks to invest in. Wall Street seems to be breathing a little easier after the initial panic over […]
On FOLD's first-quarter 2025 earnings call, investors are likely to focus on the sales of lead drug Galafold and the combo drug, Pombiliti + Opfolda.
PRINCETON, N.J., April 21, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and...
Buy healthcare stocks like WGS, THC, RIGL and ENSG for steady returns as the focus shifts to the Trump administration's healthcare policies.
We recently published a list of 10 Best Low Cost Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Amicus Therapeutics, Inc. (NASDAQ:FOLD) stands against other best low cost stocks to buy according to billionaires. Markets are wobbling, and panic is becoming the headline. At times […]
2024 Total Revenue of $528.3M, a 33% Increase Year-over-Year Projecting 2025 Total Revenue Growth of 17-24% at CER Anticipate Achieving Positive GAAP...
PRINCETON, N.J., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and...
PRINCETON, N.J., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that two oral presentations and 20 posters across...
2024 Total Revenue of $528M, Representing Significant Growth of 32% Year-Over-Year1 Strong and Growing Demand for Galafold® and Pombiliti® + Opfolda® ...
PRINCETON, N.J., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that Bradley Campbell, President and Chief...
Morgan Stanley downgraded Amicus Therapeutics Inc (NASDAQ:FOLD). Over the last year, the company has executed well commercially, met its goals financially by achieving nonGAAP profitability for 2024, and settled its Galafold patent litigation with Teva Pharmaceutical Industries Ltd. The analyst notes that Amicus is well-positioned, but expectations have increased with the company’s progress, which are now largely priced into shares. The analyst downgraded the stock to Equal-weight from Overweigh